Cargando…

Electroacupuncture Reduces Weight Gain Induced by Rosiglitazone through PPARγ and Leptin Receptor in CNS

We investigate the effect of electroacupuncture (EA) on protecting the weight gain side effect of rosiglitazone (RSG) in type 2 diabetes mellitus (T2DM) rats and its possible mechanism in central nervous system (CNS). Our study showed that RSG (5 mg/kg) significantly increased the body weight and fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jing, Xinyue, Ou, Chen, Chen, Hui, Wang, Tianlin, Xu, Bin, Lu, Shengfeng, Zhu, Bing-Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745334/ https://www.ncbi.nlm.nih.gov/pubmed/26904147 http://dx.doi.org/10.1155/2016/8098561

Ejemplares similares

Rosiglitazone activation of PPARγ suppresses fractalkine signaling
por: Wan, Yihong, et al.
Publicado: (2010)

Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
por: Cellai, I, et al.
Publicado: (2006)

Electroacupuncture Regulates Inguinal White Adipose Tissue Browning by Promoting Sirtuin-1-Dependent PPARγ Deacetylation and Mitochondrial Biogenesis
por: Tang, Qianqian, et al.
Publicado: (2021)

Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone
por: Cheng, Wing Yin, et al.
Publicado: (2016)

The PPARγ Agonist Rosiglitazone Impairs Colonic Inflammation in Mice with Experimental Colitis
por: Ramakers, Julian D., et al.
Publicado: (2007)

The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells
por: Wang, Zhenyu, et al.
Publicado: (2020)

The effects of PPARγ agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model
por: Guzeloglu, Mehmet, et al.
Publicado: (2012)

Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
por: Wang, Xue-Jiao, et al.
Publicado: (2014)

Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers
por: Step, Sonia E., et al.
Publicado: (2014)

Expression of GPR43 in Brown Adipogenesis Is Enhanced by Rosiglitazone and Controlled by PPARγ/RXR Heterodimerization
por: Hu, Jiamiao, et al.
Publicado: (2018)

What is the impact of PPAR-γ agonist-rosiglitazone on ovarian reserve after hysterectomy? An experimental study
por: GÜNDOĞDU, Burcu, et al.
Publicado: (2020)

Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
por: Wu, Yanqiao, et al.
Publicado: (2020)

Rosiglitazone-Mediated Activation of PPARγ Restores HO1 Expression in the Human Preeclamptic Placenta
por: Grimaldi, Brooke, et al.
Publicado: (2023)

Baicalin Promotes CNS Remyelination via PPARγ Signal Pathway
por: Ai, Ruo-Song, et al.
Publicado: (2022)

The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
por: Bogatkevich, Galina S., et al.
Publicado: (2012)

Activation of PPARγ by Rosiglitazone Does Not Negatively Impact Male Sex Steroid Hormones in Diabetic Rats
por: Mansour, Mahmoud, et al.
Publicado: (2009)

Retraction of “Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis”
por: Wu, Yanqiao, et al.
Publicado: (2021)

Rosiglitazone Alleviates Contrast-Induced Acute Kidney Injury in Rats via the PPARγ/NLRP3 Signaling Pathway
por: Wu, Jiayi, et al.
Publicado: (2022)

A role for CNS PPARγ in the regulation of energy balance
por: Ryan, Karen K., et al.
Publicado: (2011)

Rosiglitazone Restores Endothelial Dysfunction in a Rat Model of Metabolic Syndrome through PPARγ- and PPARδ-Dependent Phosphorylation of Akt and eNOS
por: Zhao, Zhigang, et al.
Publicado: (2011)

Influence of Rosiglitazone on the Expression of PPARγ, NF-κB, and TNF-α in Rat Model of Ulcerative Colitis
por: Mao, Jing-Wei, et al.
Publicado: (2012)

Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver
por: Lee, Samuel M., et al.
Publicado: (2021)

Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms
por: He, Qing, et al.
Publicado: (2008)

PPARγ Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice
por: Sun, Ying, et al.
Publicado: (2013)

Rosiglitazone via PPARγ-dependent suppression of oxidative stress attenuates endothelial dysfunction in rats fed homocysteine thiolactone
por: Yang, Xu-Hong, et al.
Publicado: (2015)

Rosiglitazone suppresses RANKL‐induced NFATc1 autoamplification by disrupting the physical interaction between NFATc1 and PPARγ
por: Park, Kyeong‐Lok, et al.
Publicado: (2018)

Rosiglitazone, a Ligand to PPARγ, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation
por: Sánchez-Aguilar, María, et al.
Publicado: (2019)

Expression of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ in the lung tissue of obese mice and the effect of rosiglitazone on proinflammatory cytokine expressions in the lung tissue
por: Ryu, Seung Lok, et al.
Publicado: (2013)

Rosiglitazone attenuates hypoxia-induced renal cell apoptosis by inhibiting NF-κB signaling pathway in a PPARγ-dependent manner
por: Wei, Jun-Yu, et al.
Publicado: (2022)

Enhancement of select cognitive domains with rosiglitazone implicates dorsal hippocampus circuitry sensitive to PPARγ agonism in an Alzheimer's mouse model
por: Cortez, IbDanelo, et al.
Publicado: (2020)

Retracted: Rosiglitazone Alleviates Contrast-Induced Acute Kidney Injury in Rats via the PPARγ/NLRP3 Signaling Pathway
por: Markers, Disease
Publicado: (2023)

Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats
por: Naderali, Mohammad M., et al.
Publicado: (2012)

The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism
por: Konger, Raymond L., et al.
Publicado: (2019)

SUMOylation of PPARγ by Rosiglitazone Prevents LPS-Induced NCoR Degradation Mediating Down Regulation of Chemokines Expression in Renal Proximal Tubular Cells
por: Lu, Ying, et al.
Publicado: (2013)

Rosiglitazone alleviates lipopolysaccharide-induced inflammation in RAW264.7 cells via inhibition of NF-κB and in a PPARγ-dependent manner
por: Zhou, Jing-Ping, et al.
Publicado: (2021)

GQ-16, a Novel Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Promotes Insulin Sensitization without Weight Gain
por: Amato, Angélica A., et al.
Publicado: (2012)

Immunoreactivities of PPARγ2, Leptin and Leptin Receptor in Oviduct of Chinese Brown Frog During Breeding Period and Pre-Hibernation
por: Liu, Y., et al.
Publicado: (2014)

Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?
por: Endomba, Francky Teddy, et al.
Publicado: (2020)

Rosiglitazone, an Agonist of PPARγ, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2
por: Han, ShouWei, et al.
Publicado: (2007)

Rosiglitazone promotes ENaC-mediated alveolar fluid clearance in acute lung injury through the PPARγ/SGK1 signaling pathway
por: He, Jing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sqp0imdh5qk56hlsup5g5b74r1